Discovery of PF-05212384/PKI-587: A phase 2 clinical PI3K/mTOR inhibitor

被引：0
|
作者：
Dehnhardt, Christoph M. [1 ]
Venkatesan, Aranapkam M. [1 ]
Delos Santos, Efren [1 ]
Kaloustian, Semiramis Ayral [1 ]
Broojimans, Natasja [1 ]
Hollander, Irwin [2 ]
Chen, Zecheng [1 ]
Lucas, Judy [1 ]
Mallon, Robert [2 ]
Verheijen, Jeroen [1 ]
Zask, Arie [1 ]
Khafizofa, Gulnaz [1 ]
Bursavich, Matt [2 ]
Richard, David [1 ]
Mansour, Tarek [1 ]
机构：
[1] Pfizer, Pearl River, NY 10965 USA
[2] Wyeth, Pearl River, NY 10965 USA
来源：
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY | 2014年 / 248卷
关键词：
D O I：
暂无
中图分类号：
O6 [化学];
学科分类号：
0703 ;
摘要：
287-MEDI
引用
收藏
页数：1
相关论文
共 50 条
  • [21] ANTI-TUMOR ACTIVITY OF DUAL PI3K/MTOR INHIBITORS PF-04691502 AND PF-05212384 IN GLIOBLASTOMA STEM-LIKE CELLS WITH DIFFERENTIAL PI3K PATHWAY ACTIVATION
    Tanaka, Shota
    Klofas, Lindsay K.
    Wakimoto, Hiroaki
    Borger, Darrell R.
    Iafrate, A. J.
    Batchelor, Tracy T.
    Chi, Andrew S.
    NEURO-ONCOLOGY, 2012, 14 : 26 - 26
  • [22] Discovery of the potent PI3K/mTOR dual inhibitor PF-04979064
    Cheng, Hengmiao
    Bagrodia, Shubha
    Bailey, Simon
    Baxi, Sangita M.
    Goulet, Lance
    Guo, Lisa
    Hoffman, Jacqui
    Johnson, Ted O.
    Johnson, Ted W.
    Li, Chunze
    Li, John
    Liu, Kevin
    Liu, Zhengyu
    Marx, Matthew A.
    Paderes, Gigi
    Sun, Shaoxian
    Walls, Marlena
    Wells, Peter A.
    Yang, Anle
    Yin, Min-Jean
    Zhu, Jingjiang
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2010, 240
  • [23] A Multi-Arm Phase I Study of the PI3K/mTOR Inhibitors PF-04691502 and Gedatolisib (PF-05212384) plus Irinotecan or the MEK Inhibitor PD-0325901 in Advanced Cancer
    Wainberg, Zev A.
    Alsina, Maria
    Soares, Heloisa P.
    Brana, Irene
    Britten, Carolyn D.
    Del Conte, Gianluca
    Ezeh, Patrick
    Houk, Brett
    Kern, Kenneth A.
    Leong, Stephen
    Pathan, Nuzhat
    Pierce, Kristen J.
    Siu, Lillian L.
    Vermette, Jennifer
    Tabernero, Josep
    TARGETED ONCOLOGY, 2017, 12 (06) : 775 - 785
  • [24] A Multi-Arm Phase I Study of the PI3K/mTOR Inhibitors PF-04691502 and Gedatolisib (PF-05212384) plus Irinotecan or the MEK Inhibitor PD-0325901 in Advanced Cancer
    Zev A. Wainberg
    Maria Alsina
    Heloisa P. Soares
    Irene Braña
    Carolyn D. Britten
    Gianluca Del Conte
    Patrick Ezeh
    Brett Houk
    Kenneth A. Kern
    Stephen Leong
    Nuzhat Pathan
    Kristen J. Pierce
    Lillian L. Siu
    Jennifer Vermette
    Josep Tabernero
    Targeted Oncology, 2017, 12 : 775 - 785
  • [25] PKI-587 and Sorafenib Targeting PI3K/AKT/mTOR and Ras/Raf/MAPK Pathways Synergistically Inhibit HCC Cell Proliferation
    Gedaly, Roberto
    Angulo, Paul
    Hundley, Jonathan
    Daily, Michael F.
    Chen, Changguo
    Evers, B. Mark
    JOURNAL OF SURGICAL RESEARCH, 2012, 176 (02) : 542 - 548
  • [26] The dual specificity PI3K/mTOR inhibitor PKI-587 displays efficacy against T-cell acute lymphoblastic leukemia (T-ALL)
    Gazi, Mohiuddin
    Moharram, Sausan A.
    Marhall, Alissa
    Kazi, Julhash U.
    CANCER LETTERS, 2017, 392 : 9 - 16
  • [27] First-in-human study of PF-05212384, a small molecule intravenous dual inhibitor of PI3K and mTOR in patients with advanced cancer: preliminary report on safety and pharmacokinetics
    Shapiro, G. I.
    Molina, J.
    Bendell, J.
    Brana, I.
    Spicer, J.
    Kwak, E.
    Pandya, S.
    Millham, R.
    Houk, B.
    Bell-McGuinn, K.
    EJC SUPPLEMENTS, 2010, 8 (07): : 123 - 123
  • [28] Dual PI3K/mTOR Inhibitors, GSK2126458 and PKI-587, Suppress Tumor Progression and Increase Radiosensitivity in Nasopharyngeal Carcinoma
    Liu, Tongxin
    Sun, Quanquan
    Li, Qi
    Yang, Hua
    Zhang, Yuqin
    Wang, Rong
    Lin, Xiaoshan
    Xiao, Dong
    Yuan, Yawei
    Chen, Longhua
    Wang, Wei
    MOLECULAR CANCER THERAPEUTICS, 2015, 14 (02) : 429 - 439
  • [29] PKI-587 enhances chemosensitivity of oxaliplatin in hepatocellular carcinoma through suppressing DNA damage repair pathway (NHEJ and HR) and PI3K/AKT/mTOR pathway
    Zhang, Yinci
    Xie, Chunmei
    Li, Amin
    Liu, Xueke
    Xing, Yingru
    Shen, Jing
    Huo, Zhen
    Zhou, Shuping
    Liu, Xinkuang
    Xie, Yinghai
    Cao, Weiya
    Ma, Yongfang
    Xu, Ruyue
    Cai, Shiyu
    Tang, Xiaolong
    Ma, Dong
    AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH, 2019, 11 (08): : 5134 - 5149
  • [30] Discovery of GDC-0980, a selective PI3K/mTOR inhibitor in clinical trials
    Sutherlin, Daniel P.
    Belvin, Marcia
    Bao, Linda
    Berry, Leanne
    Berry, Megan
    Castanedo, Georgette
    Edgar, Kyle
    Folkes, Adrian
    Friedman, Lori
    Heffron, Tim
    Patel, Sonal
    Olivero, Alan
    Lesnick, John
    Lewis, Cristina
    Marsters, James
    Nonomiya, Jim
    Pang, Jodie
    Prior, Wei Wei
    Salphati, Laurent
    Sampath, Deepak
    Tsui, Vickie
    Wallin, Jeff
    Wei, BinQing
    Weismann, Christian
    Zhu, Bing-Yan
    CANCER RESEARCH, 2011, 71
12345